Tandem Meetings 2023 | Retrospective study of anakinra to manage ICANS in patients treated with CAR-T therapy
Amer Beitinjaneh, MD, University of Miami, Jackson Memorial Hospital, Miami, FL, outlines the results of a retrospective study assessing the efficacy of anakinra in managing severe immune effector cell-associated neurotoxicity syndrome (ICANS) in patients treated with CAR-T therapy. The study reported that the overall median time to ICANS resolution with anakinra was shorter when compared to results from ZUMA-1 (NCT02348216) and ZUMA-2 (NCT02601313), suggesting that patients with grade 3 or higher neurotoxicity may benefit from anakinra. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
